The Bronchodilator Effect of Ultrafine Particles of Salbutamol

Not Applicable

Completed

• Conditions: Respiratory: Asthma; Respiratory; Asthma

• Registration Number: ISRCTN89168782
• Lead Sponsor: Department of Health

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2004-09-05
• Study Start: 2004-09-30
• Last Update Posted: 20 April 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 8

Inclusion Criteria

1. Age >18 years
2. The presence of mild to moderate asthma
3. Willingness and ability to give written informed consent

Potential volunteers will be identified from two sources; prospectively from patients attending Dr D Thickett's respiratory out-patient clinics at UHB trust, and from poster advertisements displayed in the staff common rooms of the Trusts critical care units. In each case, interested parties will be invited to contact the principal investigator by phone to discuss possible participation further. If they would still like to consider participation they will be sent a volunteer information sheet, a copy of the consent form and a 'reply paid' slip by mail. On receipt of the reply slip, the principal investigator will contact them again by phone to arrange a mutually convenient date for them to attend for the first study day. Formal informed written consent will be obtained when participants attend for the first study day. At no time will the participants be pressurised into taking part in any way. No inducements will be offered, but traveling expenses will be refunded if requested.
Participants will be asked if they would like their general practitioners to be informed of their participation in the study. If so, a letter explaining the study and detailing the individual's participation will be sent by first class post to the general practitioner on the first study day.

Exclusion Criteria

1. The use of > 1000 mcg Beclomethasone (or equivalent) per day
2. Unstable asthma
3. Inability or unwillingness to discontinue long acting and oral bronchodilators for 24 hours, and all short acting bronchodilators for 4 hours prior to each study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified